|
|
|
| home > white papers > Maximize the ROI of Your Post-Approval Research - Bioclinica |
|
|
 WHITE PAPERS |
|
|
Bioclinica
|
|
Maximize the ROI of Your Post-Approval Research
|
|
Expenditures in post-approval (Phase IV) research are going up across
the pharmaceutical, biotech and medical device industries. Given the
resources you’ve committed to post-approval research, you may be
wondering if you’re getting the greatest possible return on your
investment.
Discover how to harness the power of post-approval
research to increase data collection, reduce resource burn, save money,
and maximize your ROI!
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Premier Research Deepens Support for Oncology Sponsors By Expanding Oncology Leadership Team
As the
number of next-generation oncology therapies in the clinical trial pipeline
surges, Premier
Research today announced three new oncology leadership team hires to
strengthen the company’s expertise in the fast-growing areas of cell and gene
therapies and immuno-oncology.
More info >> |
|
 |
White Papers |
 |
|
Convergence in the Pharmaceutical Market
PCI Pharma Services
Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >> |
|
|
|
